ProSciento

Executive Summary

ProSciento is a specialized clinical research organization (CRO) exclusively focused on metabolic and rare diseases, with over two decades of experience based in San Diego. The company provides full-service clinical trial design and execution, leveraging deep scientific expertise and advanced methodologies to support drug development in obesity, diabetes, MASLD/MASH, and related conditions. Positioned to benefit from the surge in metabolic and rare disease programs, ProSciento offers sponsors a tailored approach that reduces trial timelines and enhances data quality. The company's niche focus and established reputation make it a key partner for biopharma companies advancing therapies in these high-growth areas. Upcoming catalysts include new large contract wins and service expansions that could drive revenue growth and solidify its market position.

Upcoming Catalysts (preview)

• Q4 2026Major Contract Win for a Large Phase 3 Obesity/MASH Trial65% success
• Q2 2027Expansion of Service Offerings into Pediatric Rare Metabolic Diseases50% success
• Q1 2027Strategic Partnership to Enhance Digital Biomarker Capabilities40% success